Wikisage, the free encyclopedia of the second generation, is digital heritage
Epilepsy: Difference between revisions
m (→Links) |
([[) |
||
Line 22: | Line 22: | ||
|[[,,,,]] | |[[,,,,]] | ||
|- style="vertical-align:top; background:#ffffff;" | |- style="vertical-align:top; background:#ffffff;" | ||
|align="left" style="background:#99ff99"|'''INN''' |||[[Generic]] | |align="left" style="background:#99ff99"|'''[[International Nonproprietary Name|INN]]''' |||[[Generic]] | ||
|slow release | |slow release | ||
|- style="vertical-align:top; background:#ffffff;" | |- style="vertical-align:top; background:#ffffff;" |
Revision as of 17:56, 29 July 2015
Classification of ethiology could divided in four categories:
- idiopathic epilepsy
- symptomatic epilepsy
- provoked epilepsy
- cryptogenic epilepsy
[1] It is difficult to distinguish between genetic and cryptogenic syndromes.
Morbility data is difficult to interpret when WHO[2] states 50-70 millions persons[3] suffers epilepsy[4]
nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance wih AED[5]
Medicines | ||||
type | ,,, | ,,,, | ||
INN | Generic | slow release | ||
carbamazepine | normal | xr | ||
lamotrigine | normal | xr | ||
levetiracetam | normal | xr | ||
oxcarbazepine | ... | xr | ||
phenitoin | ... | xr | ||
valproate | xr | |||
topiramate | xr | |||
AED |
ILAE Classification
See also
A new perspective for Epileptic Disorders
Links
Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population
The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis
The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs
References: |
|